XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Third-Party Arrangements
 9 Months Ended
Sep. 30, 2025
Related Party Transactions [Abstract]  
Third-Party Arrangements Third-Party Arrangements
On June 2, 2021, Organon and Merck & Co., Inc. (“Merck”) entered into a Separation and Distribution Agreement (the “Separation and Distribution Agreement”). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the “Separation”).

The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation. As of September 30, 2025, only one jurisdiction remains under an Interim Operating Model Agreement.

Under the manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the Company, or its applicable affiliate. For details on the rights and responsibilities of the parties under the agreements, refer to Note 17 “Third-Party Arrangements” to the audited Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

The amounts due under such agreements were:
($ in millions)September 30, 2025December 31, 2024
Due from Merck in Accounts receivable
$162 $148 
Due to Merck in Accounts payable
401 362 

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Sales $18 $25 $55 $82 
Cost of sales 15 24 47 76